British journal of clinical pharmacology · 2018
Acenocoumarol as an alternative anticoagulant in a patient with warfarin-related nephropathy.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Behera Sapan Kumar, Xavier Alphienes Stanley, Selvarajan Sandhiya, Munuswamy Hemachandren, Haridasan Satish, Srinivas Bheemanathi Hanuman
Аннотация
ADVERSE EVENT: Warfarin-related nephropathy.
DRUG IMPLICATED: Warfarin.
THE PATIENT: A 31-year-old female, managed with warfarin for rheumatic heart disease with atrial fibrillation.
EVIDENCE THAT LINKS THE DRUG TO THE EVENT: There were no alternative causes of nephropathy that could have caused the adverse event in this patient.
MANAGEMENT: Shifting the drug from warfarin to acenocoumarol.
MECHANISM: Difference in renal elimination between warfarin and acenocoumarol.
IMPLICATION FOR THERAPY: Clinicians should be aware of this rare adverse effect of warfarin, and acenocoumarol can be considered as an alternative therapy for this condition.
HYPOTHESES TO BE TESTED: Further prospectively designed studies are needed to consider acenocoumarol as an alternative therapy in warfarin-related nephropathy.
DRUG IMPLICATED: Warfarin.
THE PATIENT: A 31-year-old female, managed with warfarin for rheumatic heart disease with atrial fibrillation.
EVIDENCE THAT LINKS THE DRUG TO THE EVENT: There were no alternative causes of nephropathy that could have caused the adverse event in this patient.
MANAGEMENT: Shifting the drug from warfarin to acenocoumarol.
MECHANISM: Difference in renal elimination between warfarin and acenocoumarol.
IMPLICATION FOR THERAPY: Clinicians should be aware of this rare adverse effect of warfarin, and acenocoumarol can be considered as an alternative therapy for this condition.
HYPOTHESES TO BE TESTED: Further prospectively designed studies are needed to consider acenocoumarol as an alternative therapy in warfarin-related nephropathy.